The Latest Research News from the Health Disparities Channel
NewswiseThe latest research news from the Health Disparities Channel.
The latest research news from the Health Disparities Channel.
Take breaks when binge-watching TV to avoid blood clots, say scientists. The warning comes as a study reports that watching TV for four hours a day or more is associated with a 35% higher risk of blood clots compared with less than 2.5 hours. The research is published today in the European Journal of Preventive Cardiology, a journal of the ESC.1
Scientists at Northwestern Medicine and The University of Texas MD Anderson Cancer Center have identified natural nano-bubbles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients and discovered these nano-sized particles can block infection from broad strains of SARS-CoV-2 virus in preclinical studies.
The American College of Surgeons (ACS) STOP THE BLEED® program recently announced it has signed with a new vendor, North American Rescue®, LLC (NAR), to offer STOP THE BLEED® Kits, equipment, and other bleeding control materials to the public through its online shop.
Researchers from MD Anderson and Northwestern University have identified natural extracellular vesicles containing the ACE2 protein in the blood of COVID-19 patients that act as decoys to block infection from SARS-CoV-2
In Review of Scientific Instruments, researchers have developed devices to automate blood smears. Their devices, called autohaem smear and smear+, can consistently create high-quality smears equivalent to those created by human experts, automating the smearing process so every smear is correct and consistent. A key goal of the project was to make the devices accessible to as many people as possible, so the researchers designed their devices to be easy to build, using readily available or 3D-printed components.
Direct oral anticoagulants should be considered the standard of care to treat adult patients with cancer-associated thrombosis, according to a new, ongoing study by Mayo Clinic researchers.
The Cedars-Sinai Cancer Blood & Marrow Transplant Program’s one-year patient survival rate exceeded expectations compared to transplant centers in the U.S. whose similar patients underwent allogeneic transplants, according to a national report that tracks those outcomes.
A critical shortage of blood, which has stretched supplies thin nationwide, threatens hospitals' ability to provide many types of patient care. The Red Cross has just declared the first-ever national blood crisis. A blood bank director with nearly 40 years of experience urges every eligible person to step up and make an appointment to donate as soon as possible.
What does a blood shortage mean for patients? How did we get here? And why Type O? A Penn State Health blood bank director weighs in.
A defective gene, normally found in blood cancers, could be treated with drugs already available for cancers with similar gene defects, scientists at Queen’s University Belfast and the University of Birmingham have revealed.
New research in the January 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined the impact of septic shock on people with hematologic malignancies, finding 67.8% died in fewer than 28 days and only 19.4% remained alive after 90 days.
Over the course of more than three decades studying sickle cell disease and caring for patients, Thomas Coates, MD, has learned an important lesson: listen to the mothers. It is their detailed accounts of their children’s pain that inspired his current research focus.
The January 2022 issue of Toxicological Sciences launches the New Year with investigations in clinical and translational toxicology, as well as emerging technologies, methods, and models.
Aberrant splicing of messenger RNAs encoding surface antigen CD22 leads to downregulation of this protein in pediatric B-lymphoblastic leukemia (B-ALL), rendering malignant cells resistant to the effects of CD22-directed immunotherapies, according to a recent study by researchers at Children’s Hospital of Philadelphia (CHOP). The findings could allow oncologists to screen new patients to see if their leukemic cells contain alternatively spliced CD22 mRNA variants, which could reveal which patients might not respond to anti-CD22 therapies and would need alternative treatment plans. The study was published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.
Computer simulations from UC San Diego School of Medicine reveal the action mechanism and substrate specificity of an important blood enzyme. These findings open the door for new therapeutics against cardiovascular disease, and further support a unifying theory of phospholipase function.
Researchers have identified a biomarker in human platelets that tracks the extent of depression.
South African geneticist Ambroise Wonkam, M.D., Ph.D., D.Med.Sc., has been selected as Johns Hopkins Medicine’s director of the Department of Genetic Medicine and the McKusick-Nathans Institute of Genetic Medicine.
A molecular building block of many animal proteins, the amino acid valine, plays a key role in cancerous growth seen in T cell acute lymphoblastic leukemia, a new study shows.
Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Icahn School of Medicine at Mount Sinai showed for the first time that artificial intelligence (AI) algorithms can detect signs of these clots in electrocardiograms (EKGs), a finding which may one day help doctors with screening.
Although unproven, this novel sickle cell therapy serves as a potential cure. More measures need to be taken to determine long-term function and organ improvement.
UC Davis Health researchers showed that blocking IL-6 and TNF cytokines provides a more effective approach to preventing life-threatening graft-versus-host-disease, an inflammatory condition that develops in patients after their allogeneic hematopoietic stem cell transplantation.
Alloplex Biotherapeutics and Hackensack Meridian Health announce Equity Investment
A new review explores the physiology behind and proposed management strategies for body-wide symptoms of the post-acute sequelae of SARS-CoV-2 (PASC), otherwise known as “long COVID.” The review is published ahead of print in the American Journal of Physiology-Cell Physiology.
Researchers at Washington University School of Medicine in St. Louis have shown, in a small clinical trial, that an immunotherapy harnessing pre-activated natural killer cells can help some children and young adults with recurrent AML and few other treatment options.
A drug combination can safely prevent transplanted stem cells (graft) from attacking the recipient’s (host) body, allowing them to develop into healthy new blood and immune cells, a new study shows.
Blood clots or thromboembolic complications in patients with COVID-19 are associated with increased levels of various proteins that cause blood to clot, compared with people with blood clots unrelated to COVID-19, according to a small study by Yale Cancer Center researchers. These findings may offer insights into novel therapeutic strategies to treat patients with COVID-19 related blood clots. The findings were reported today at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia.
The final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The findings are being presented today at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia.
Combination therapies including venetoclax and another therapy have displayed promising results against subtypes of acute myeloid leukemia (AML) that are particularly difficult to treat, including relapsed or refractory AML with a specific mutation, high-risk AML and treated secondary AML. Researchers from The University of Texas MD Anderson Cancer Center presented numerous studies involving venetoclax combination therapy for AML at the 2021 American Society of Hematology (ASH) Annual Meeting.
The American Society of Hematology (ASH) has recognized Stephen Ansell, M.D., of Mayo Clinic with the highly distinguished Ernest Beutler Lecture and Prize as part of its Honorific Awards to recognize exemplary hematologists who have made significant contributions to the field and have been nominated by ASH members.
Young patients with chronic lymphocytic leukemia (CLL) can enjoy long remissions on the drug ibrutinib, but must stay on it indefinitely to keep the cancer in remission. A new study by Dana-Farber Cancer Institute researchers suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions of the disease.
Researchers from Rutgers Cancer Institute of New Jersey, the state’s only NCI-designated Comprehensive Cancer Center, examined the effects of SIRT1, an enzyme located primarily in the cell nucleus that contributes to cellular regulation on the transformation of T-cells.
For patients with the blood cancer multiple myeloma, vaccination against COVID-19 provides some protection against coronavirus infection but to a far lower degree than the general population of cancer survivors, a new study by Dana-Farber Cancer Institute investigators shows.
Roswell Park Comprehensive Cancer Center hematology experts in leukemia, lymphoma and other specialties will present new research at the 63rd annual meeting of the American Society of Hematology (ASH), which begins today in Atlanta, Georgia. The many research projects to be highlighted include breakthrough research on CAR T cell therapy, immunotherapy, leukemia, lymphoma and the management of genetic mutations in aggressive and rare blood cancers.
Mount Sinai physician-scientists have found that a novel therapy for the bone marrow cancer myelofibrosis is safe and well-tolerated and is associated with modest improvements in patients in a Phase 1b clinical trial. They shared their findings during an oral presentation at the American Society of Hematology annual meeting in December.
The first results from the largest screening study yet conducted in the U.S. of individuals at above-average risk for the blood cancer multiple myeloma have revealed higher rates of a myeloma precursor condition in older adults who are Black or who have a close family member with a current or past blood cancer.
Chimeric antigen receptor T-cell therapy or CAR T is a breakthrough treatment for patients with certain types of blood cancers. The cellular therapy uses a patient’s own immune cells that are reengineered to better seek out and destroy cancer cells. The single infusion treatment is approved for patients who have relapsed after two or more types of therapy but results from the ZUMA-7 clinical trial show lymphoma patients can benefit from receiving the CAR T product axicabtagene ciloleucel (Yescarta) sooner.
Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy. These results were reported at the 2021 American Society of Hematology (ASH) Annual Meeting.
Mount Sinai scientists have become the first to report a potentially serious side effect related to a new form of immunotherapy known as CAR-T cell therapy, which was recently approved for the treatment of multiple myeloma. Their findings were published as a case study in Nature Medicine in December.
Research underway at Rutgers Cancer Institute of New Jersey will contribute to the development of new cancer treatments that are based on the administration of cancer-fighting immune cells to patients.
Researchers from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a part of the Georgetown Lombardi Comprehensive Cancer Center, will present updates on treatment advances in multiple myeloma, lymphoma, leukemia, and bone marrow transplantation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually and live at the Georgia World Congress Center in Atlanta from December 11-14, 2021.
A new targeted nanomedicine treatment developed at the University of Chicago has shown promise in reducing vascular lesions caused by atherosclerosis in a mouse model.
Biomedical scientists at LMU have found a new marker in the blood of Covid-19 patients. It furnishes insights into the course and development of the disease and could lead to better diagnoses.
New research shows liquid biopsy for HPV-associated head and neck cancer is more than 98% accurate and obtained a diagnosis 26 days quicker on average than conventional tissue biopsy, in addition to costing 38% less. With HPV-associated head and neck cancer rates on the rise, there is a great need for more accurate, less-invasive, faster and less expensive diagnostic tests.
Seattle Children’s today announced five oral presentations at the American Society of Hematology (ASH) annual meeting, the world’s premier event in malignant and non-malignant hematology set to take place from Dec. 11-14.
Researchers have developed microbubbles to acoustically detect blood oxygen levels, since the microbubble shells are altered by structural hemoglobin changes in response to oxygen. The gas filling of the microbubbles causes them to oscillate and vibrate when ultrasound is applied, scattering energy and generating an acoustic response that can be detected by a clinical ultrasound scanner. Preliminary results show a strong correlation between oxygen concentration and the acoustic bubble response.
A statistical model developed by Université de Montréal researchers uses a blood biomarker of SARS-CoV-2 to identify infected patients who are most at risk of dying of COVID-19.
The California Institute for Regenerative Medicine (CIRM) approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.
Clonal hematopoiesis, a condition in which mutations associated with blood cancers are found in the blood of healthy people, is common with aging. When looking for appropriate stem cell/bone marrow donors, clinicians tend to stay away from older donors with clonal hematopoiesis (CH) because of concerns about passing potentially premalignant stem cells to the recipient.
Jeffrey L. Carson, MD, whose research has profoundly reshaped transfusion medicine is being honored by the American College of Physicians (ACP) with the John Phillips Memorial Award for Outstanding Work in Clinical Medicine for his career-long journey to improve health outcomes for patients.